Oncology

Myeloproliferative Neoplasms

Advertisment
Importance of Disease-Related Symptoms in Patients With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms

Importance of Disease-Related Symptoms in Patients With Myeloproliferative Neoplasms

expert roundtables
By Katherine Walsh, MD, FACP; Rami S. Komrokji, MD; Ruben A. Mesa, MD, FACP
Overcoming Treatment Challenges in Polycythemia Vera
Myeloproliferative Neoplasms

Overcoming Treatment Challenges in Polycythemia Vera

expert roundtables
By Katherine Walsh, MD, FACP; Rami S. Komrokji, MD; Ruben A. Mesa, MD, FACP
Management of Toxicities in Patients Being Treated for Polycythemia Vera
Myeloproliferative Neoplasms

Management of Toxicities in Patients Being Treated for Polycythemia Vera

patient care perspectives
By Ruben A. Mesa, MD, FACP
Nonadherence to Cytoreductive and/or Antithrombotic Therapy in Patients With Polycythemia Vera
Myeloproliferative Neoplasms

Nonadherence to Cytoreductive and/or Antithrombotic Therapy in Patients With Polycythemia Vera

patient care perspectives
By Katherine Walsh, MD, FACP
Genomics and Personalized Prognosis in Myeloproliferative Neoplasms
Myeloproliferative Neoplasms

Genomics and Personalized Prognosis in Myeloproliferative Neoplasms

clinical topic updates
By Rami S. Komrokji, MD
Load More   

Experts in Myeloproliferative Neoplasms

+0

Meet the Experts   

Advertisment